Century Therapeutics Stock News

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu

PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun

PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu

PHILADELPHIA, March 23, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immu

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc  FATE and Century Therapeuti

The big drugmaker is gaining access to Century Therapeutics'' off-the-shelf CAR-T programs.

The stock price of Century Therapeutics Inc (NASDAQ: IPSC) increased by 14.52% in the most recent trading session. This is why it happened.

Century Therapeutics Inc (IPSC) shares closed today 14.5% higher than it did at the end of yesterday. The stock is currently down 16.6% year-to-date, down 42.1% over the past 12 months, and down 42.1% over the past five years. Today, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $16.83 and as low as $12.47 this week.Shares closed 54.0% below its 52-week high and 21.4% above its 52-week low.Trading volume this week was 43.5% lower than the 10-day average and 66.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 6287.3% The company's stock price performance over the past 12 months lags the peer average by 467.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cell therapy company Century Therapeutics will receive a $100 million up front payment and $50 million in equity investment from Bristol Myers Squibb in a deal announced Monday.

Century Therapeutics Inc (NASDAQ: IPSC ) and Bristol Myers Squibb Co (NYSE: BMY ) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs for hematologic malignancies and solid tumors. The first two programs include a program in acute myeloid leukemia and a program in multiple myeloma, which could … Full story available on Benzinga.com

Century Therapeutics (IPSC) soars 13.5% premarket after announcing research collaboration and license agreement with and Bristol Myers Squibb (BMY) to develop and commercialize up to

Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) p

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immun